Loading
A pair of tests on a thyroid nodule needle sample, one reading DNA and RNA fusions and one reading small regulatory RNAs, to judge whether an uncertain nodule is likely to be cancer.
Interpace Biosciences describes ThyGeNEXT as a DNA mutation panel plus an RNA fusion panel (ALK, BRAF, NTRK, PPARG, RET, THADA) and mRNA markers (NKX2-1, PAX8, TBP, USP33), billed under PLA code 0245U, "mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers"; ThyraMIR v2 "analyzes microRNA signatures". In a multicentre study of indeterminate nodules the combined test had 95 per cent sensitivity, 90 per cent specificity, a 97 per cent negative predictive value and a 75 per cent positive predictive value (Lupo 2020).
ThyGeNEXT sequences DNA mutations, RNA fusions and four mRNA markers; ThyraMIR v2 measures a microRNA signature; together they classify an indeterminate thyroid nodule.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ThyGeNEXT and ThyraMIR v2" OR ABSTRACT:"ThyGeNEXT and ThyraMIR v2" OR TITLE:"ThyGeNEXT" OR ABSTRACT:"ThyGeNEXT" OR TITLE:"ThyraMIR" OR ABSTRACT:"ThyraMIR" OR TITLE:"Interpace multiplatform thyroid test" OR ABSTRACT:"Interpace multiplatform thyroid test") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ThyGeNEXT and ThyraMIR v2, not a curated reading list.
Shares the tags test, rna.
Shares the tags test, rna.
Shares the tags test, rna.
Shares the tags test, rna.
Shares the tags test, rna.
Shares the tags test, rna.
Shares the tags test, rna.
Shares the tags test, rna.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/